Effect of daratumumab as single agent or in combination in high risk relapse refractory (RR) myeloma population.
Phase of Trial: Phase IV
Latest Information Update: 21 Dec 2017
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 21 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.